Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,407 matching trials from the live ClinicalTrials.gov search.
Conditions
Local Anesthesia
Interventions
Iontophoretic Drug Delivery System with Lidocaine/Epinephrine, Iontophoretic Drug Delivery System with Epinephrine
Device
Lead sponsor
Dharma Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Anaheim, California • Overland Park, Missouri
Conditions
Mothers
Interventions
Text-based mentorship, Control text messaging
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Major Depressive Disorder
Interventions
apimostinel, Placebo
Drug
Lead sponsor
Syndeio Biosciences, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rogers, Arkansas
Completed No phase listed Observational Accepts healthy volunteers

Enhanced Tactile (Touch) Spatial Acuity in Upper Limb Amputees

NCT00028210
Conditions
Amputation
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Spinal Cord Injuries and Disorders (SCI/D)
Interventions
Caring Connections, Attention control
Other
Lead sponsor
Chicago Association for Research and Education in Science
Other
Eligibility
18 Years to 90 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Hines, Illinois
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
IFN-β-1a (Rebif®)
Drug
Lead sponsor
Waukesha Memorial Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Waukesha, Wisconsin
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

NCT02231190
Conditions
Tendon Injuries
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

NCT02371668
Conditions
H1N1 Influenza Healthy Volunteers
Interventions
CR6261, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Use of Driving Tests to Evaluate Patient Performance on Oral Opioids

NCT00659035
Conditions
Chronic Pain
Interventions
Not listed
Lead sponsor
Asokumar Buvanendran
Other
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Exposure
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older
Enrollment
5,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Conditions
Bleeding
Interventions
Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Conditions
Systemic Lupus Erythematosus
Interventions
CUG252, Placebo
Drug
Lead sponsor
Cugene Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Recruiting Not applicable Interventional Accepts healthy volunteers

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
Conditions
Nicotine Dependence
Interventions
Belsomra, Placebo, Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036
Conditions
Healthy Subjects
Interventions
MGD010, Placebo, Hepatitis A vaccine
Drug · Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bacterial Infections
Interventions
QPX9003 for IV Infusion, Placebo for IV infusion
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-KHK, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Vista, California • Lake Worth, Florida + 8 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Not listed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Biomarker for Seizures

NCT03441867
Conditions
Seizure Disorder, Seizure Disorder, Post Traumatic, Traumatic Brain Injury, Non-Epileptic Seizure, Conversion Disorder, Magnetic Resonance Imaging, Head Injury, Epilepsy
Interventions
Cognitive Behavioral Therapy for Seizures, Standard Medical Care
Behavioral · Other
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island
Conditions
Healthy
Interventions
Talampanel, Moxifloxacin, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

NCT01430312
Conditions
Healthy
Interventions
azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
Interventions
glucagon stimulation test and insulin tolerance test
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Cleveland, Ohio • Portland, Oregon + 1 more
Conditions
Healthy Volunteer
Interventions
Placebo, RO5508887
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Completed Phase 1 Interventional Accepts healthy volunteers

Implant Pharmacokinetic and Pharmacodynamic Study

NCT03634137
Conditions
Healthy
Interventions
Afamelanotide Group 1, Afamelanotide Group 2
Drug
Lead sponsor
Clinuvel Pharmaceuticals Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota